Computational Biology Labs
@ IRIBHM Jacques E. Dumont

Maxime Tarabichi
PI
πŸŽ“ 🧬 πŸ› οΈ

Research

In our cells the initial genomes inherited from our parents evolve over time through the accumulation of somatic mutations. Most of these are silent and very few cell genomes will lead to malignant growth. In our lab, we study how different classes of somatic changes, including single nucleotide substitutions and copy-number changes accumulate over time on the parental genomes in our cells leading up to the observed cancer genomes. These continue accumulating in cancer cells leading to intra-tumour genetic heterogeneity.
We develop bioinformatics tools to detect and characterise those variants from sequencing data, and methods to time them or assign them to parental genomes. Our current toolset allows us to infer how these changes accumulated over time from the fertilised egg to surgical resection, and how they continue accumulating in the tumour tissue. We are in particular interested in polyploidisation events common in cancer, and are developing a framework to study their prevalence and association with increasing chromosomal instability.
One particular focus of the lab is on thyroid tissues and cancers, as well as chromosomally instable tumours including sarcomas.
Please visit the page of ASCAT.sc , our copy-number caller, developed with the Van Loo lab.

Biography

Maxime studied engineering at the Faculty of Applied Sciences of the UniversitΓ© Libre de Bruxelles (ULB), where he specialised in medical informatics and imaging. He then pursued a PhD in computational biology under the supervision of Vincent Detours at the Faculty of Medicine (ULB), focusing on the integration of omics profiles in thyroid cancers. He later joined Peter Van Loo’s group at the Francis Crick Institute, where he studied intratumour genetic heterogeneity and cancer genome evolution, with a particular focus on rare sarcomas. During this time, he also visited Thierry Voet’s lab at the Wellcome Sanger Institute and developed expertise in single-cell sequencing. He is currently an Associate Professor and Group Leader at IRIBHM – ULB, as well as a visiting scientist at the MD Anderson Cancer Center and University College London. His lab investigates the somatic and cancer genome evolution of different tissues, including in the context of sarcomas and thyroid cancers.

Publications

Thyroid cancer cell lines: an overview β€” Frontiers in Endocrinology, 2012
Neutral tumor evolution? β€” Nature Genetics, 2018
Inferring structural variant cancer cell fraction β€” Nature Communications, 2020
Thyroid cancer under the scope of emerging technologies β€” Molecular and Cellular Endocrinology, 2021
Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers β€” The Journal of Clinical Endocrinology & Metabolism, 2018
Creating Standards for Evaluating Tumour Subclonal Reconstruction β€” bioRxiv (Cold Spring Harbor Laboratory), 2018
Pervasive intra-tumour heterogeneity and subclonal selection across cancer types β€” Cancer Research, 2018
Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcome β€” bioRxiv (Cold Spring Harbor Laboratory), 2024
Crowd-sourced benchmarking of single-sample tumour subclonal reconstruction β€” bioRxiv (Cold Spring Harbor Laboratory), 2022